Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Cervical Cancer Recurrent × tislelizumab × Gynecologic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Uterine Cervical Neoplasms 7 Ovarian Neoplasms 2 Endometrial Neoplasms 2 Turcot syndrome 1 Testicular Germ Cell Tumor 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Sarcoma 1 Neoplasms 1 Mesothelioma 1 Melanoma 1 Colorectal Neoplasms, Hereditary Nonpolyposis 1 Cervical Cancer Recurrent 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

tislelizumab 1 RC48 antibody 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06063018 2023-10-02

RC48 Combined With Tislelizumab for Second-line Treatment of HER2 Expression in Recurrent Cervical Cancer

Peking Union Medical College Hospital

Phase 2 Recruiting

Cervical Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡